

Sixth International Meeting

# Metronomic Chemotherapy in Oncology

**Monday, October 1, 2018** and **Tuesday, October 2, 2018**  
8 a.m. to 6 p.m. 8 a.m. to 3:30 p.m.

**Michigan State University  
Grand Rapids Research Center**  
400 Monroe Avenue, NW  
Grand Rapids, MI 49503

## Description and Objectives

Following previous meetings held in Mumbai, Haifa, Marseille, Boston and Milan, the next workshop/meeting on metronomic chemotherapy will be held in Grand Rapids, Michigan, on October 1 and 2, 2018. Principal organizers are Drs. Nicolas Andre (France), Robert Kerbel (Canada) and Giselle Saulnier Sholler (United States). Recent promising updates regarding clinical trial results, including drug combinations, in a number of indications (e.g., breast, colorectal and ovarian cancers), as well as pediatric malignancies, will be summarized along with basic research advances, including immunotherapeutic, antiangiogenic and tumor cell targeting mechanisms mediated by metronomic chemotherapy.

The conference is designed to highlight how to integrate angiogenesis and immunity, discuss emerging techniques and new strategies to identify and characterize precision targets, and facilitate national and international research coordination and collaboration among participants.

## Keynote Speakers

**Robert Kerbel, PhD**, Canada

**Elisabetta Munzone, MD**, Italy

**Anil Sood, MD**, United States



# Agenda

**Monday, October 1, 2018**

Michigan State University Grand Rapids Research Center

8 a.m. to 8:30 a.m.	<b>Breakfast and Welcome</b>
8:45 a.m. to 10:15 a.m.	<b>Preclinical: Angiogenesis/Immunity/Stem Cells</b> Chair: Giselle Sholler, MD  <b>Immunological response to anti-cancer therapy: lessons learned from MTD vs. LDM chemotherapy regimens'</b> Yuval Shaked, PhD Technion Integrated Cancer Center (TICC), Haifa, Israel  <b>Metronomic Targeting of Cancer Stem Cells</b> Giselle Sholler, MD Helen DeVos Children's Hospital, United States  <b>A Novel Therapeutic Pillar, Anakoinosis: Tumor Tissue as a Multilevel Design Space</b> Albrecht Reichler, MD, PhD Regensburg University Hospital, Regensburg, Germany  <b>Metronomic Chemotherapy-Based Regimens: Combination Versus Sequential Administration</b> Giulio Francia, PhD University of Texas at El Paso, Texas, United States
10:15 a.m. to 10:30 a.m.	<b>Break</b>
10:30 a.m. to 11:15 a.m.	<b>Metronomic Chemotherapy: Looking Back, Looking Forward</b> Keynote: Robert Kerbel, PhD University of Toronto, Toronto, Canada
11:15 a.m. to 11:45 a.m.	<b>Short Communications</b> Traore Fouseiny, MD Gabriel Toure Hospital, Bamako, Mali  Irene Slavic, MD Medical University of Vienna, Austria
11:45 a.m. to 1 p.m.	<b>Lunch</b>

continued

# Agenda

**Monday, October 1, 2018**

Michigan State University Grand Rapids Research Center

1 p.m. to 2:30 p.m.	<p><b>Preclinical: Pharmacology: Models/ Microenvironment/Nanotechnology</b></p> <p><b>Metronomics for Triple Negative Breast Cancer Treatment</b> Graciela Scharovsky, PhD National University of Rosario (UNR) , Rosario, Argentina</p> <p><b>Metronomic chemotherapy in veterinary medicine: Opportunities to inform clinical translation</b> Anthony Mutsaers, DVM, PhD Ontario Veterinary College, Guelph, Ontario, Canada</p> <p><b>High-Throughput Chemogenomics Identifies Novel Therapeutic Targets in Refractory Cancers: Toward Next-Generation Drug Repurposing</b> Eddy Pasquier, PhD Marseille Cancer Research Center (CRCM), Marseille, France</p> <p><b>Metronomic Chemotherapy Enhances Anti-Tumor Efficacy by “Sparing” Tumor Stroma, Stemness and Immunity</b> Kelvin Tsai, MD, PhD Taipei Medical University, National Health Research Institutes, Taipei, Taiwan</p>
2:30 p.m. to 2:45 p.m.	<b>Break</b>
2:45 p.m. to 3:30 p.m.	<p><b>Metronomic Chemotherapy for Breast Cancer— Clinical Experience</b> Keynote: Elisabetta Munzone, MD European Institute of Oncology, Milano, Italy</p>
3:30 p.m. to 3:45 p.m.	<b>Third Barton Kamen Prize</b>
4 p.m. to 5:30p.m.	<b>Posters Session</b>
5:30 p.m.	<b>Bus to Dinner</b>
6 p.m.	<b>Welcome and Dinner</b>

continued

# Agenda

**Tuesday, October 2, 2018**

Michigan State University Grand Rapids Research Center

6:30 a.m. to 7:30 a.m.	<b>Early Morning Metronomic Run</b> Led by Nicolas Andre
8 a.m. to 8:30 a.m.	<b>Breakfast and Welcome</b>
8:45 a.m. to 10:15 a.m.	<b>Clinical Therapies—Session 1</b> Chair: Nicolas Andre, MD, PhD Hospital of Marseille (AP-HM), Marseille, France <b>Targeting Oncogenic MYCN With Low-Dose Metronomic Topotecan—Preclinical Studies and Implications for the Clients</b> Sabine Taschner-Mandl, PhD Children's Cancer Research Institute, Wien, Austria <b>Topic to be Determined</b> Shripad Banavali, MD Tata Memorial Center, Mumbai, India <b>Metronomic Therapy in High-Risk Neuroblastoma Patients</b> Frank Berthold, MD University Hospital of Cologne, Cologne, Germany <b>Artificial Intelligence (AI)-enhanced combination metronomic chemotherapy</b> Giannoula Lakka Klement, MD, FRCP (C) CSTS Health Care Inc. Toronto, Canada <b>Metronomic Chemotherapy and Clonal Heterogeneity</b> Nicolas Andre, MD, PhD Hospital of Marseille (APHM), Marseille, France
10:15 a.m. to 10:30 a.m.	<b>Break</b>
10:30 a.m. to 11:15 a.m.	<b>Metronomic Therapy: Lessons From the Lab and Clinic</b> Keynote: Anil Sood, MD MD Anderson Cancer Center, Texas, USA
11:15 a.m. to 11:45 a.m.	<b>Short Communications</b> Lina Ghibelli, PhD University of Rome, Rome, Italy Jackie Kraveka, DO Medical University of South Carolina, South Carolina, United States
11:45 a.m. to 1 p.m.	<b>Lunch</b>

continued

# Agenda

**Tuesday, October 2, 2018**

Michigan State University Grand Rapids Research Center

1 p.m. to 2:30 p.m.

## **Clinical Therapies—Session 2**

Chair: TBD

### **Gutta Cavat Lapidem: DEVEC Metronomic Schedule for Aggressive B and T Cell Lymphomas**

Christina Cox, MD

Sant' Andrea University Hospital, Rome, Italy

### **Low-Dose Maintenance Chemotherapy in Rhabdomyosarcoma**

Daniel Orbach, MD

Institut Curie, Paris, France

### **Individualized Treatment of Children With High-Risk Solid Tumors in Real-Life Scenarios: Comparative Patient Series Analysis**

Michal Kyr, MD

University Hospital Brno, Brno, Czech Republic

### **Metronomic Low-Dose Cyclophosphamide for Advanced Metastatic Colorectal Cancer**

Andrew Godkin, MD, PhD

Cardiff University, Cardiff, Wales

### **Low-Dose Cyclophosphamide, Anti-Tumor T Cell Responses and the Role of Gut Bacteria**

Martin Scurr, Research Associate

Cardiff University, Cardiff, Wales

2:30 p.m. to 3 p.m.

## **Short Communications - to be determined**

3 p.m. to 3:30 p.m.

## **Conclusions and Farewell**



# Registration

The registration fee includes tuition and materials for one attendee, breakfast, lunch and snacks.

Academia, Industry, Organization, Individual: \$200

Student, Postdoctorate: \$50

To register for the event, please visit **[metronomics.org](http://metronomics.org)**.

# Abstract

Abstracts are due September 5, 2018 (300-word maximum)  
for selection of oral or poster presentation.

